Children receiving immunosuppressive treatment for cancer are at high risk for invasive pneumococcal disease. The 13‐valent pneumococcal conjugate vaccine (PCV13) can prevent pneumococcal disease in healthy children; however, there is… Click to show full abstract
Children receiving immunosuppressive treatment for cancer are at high risk for invasive pneumococcal disease. The 13‐valent pneumococcal conjugate vaccine (PCV13) can prevent pneumococcal disease in healthy children; however, there is an absence of literature regarding the benefit of PCV13 in immunocompromised children with cancer.
               
Click one of the above tabs to view related content.